Ajanta Pharma Q4 Review - Domestic Formulation, Institutional Anti-Malaria Drive Earnings: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Ajanta Pharma Ltd. delivered a better-than-expected performance, led by a strong growth revival in domestic formulation and better operating leverage.
Growth prospects in branded generics exports (Asia) are expected to improve as the Covid-19-led supply chain disruption eases.
We have raised our estimates by 3%/5% for FY22/FY23E, factoring in:
a better outlook for the pain management therapy in the DF segment,
reduced operating expenses in DF over the medium term due to Covid-19-led restrictions,
new abbreviated new drug application launches, and
better capacity utilisation.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.